Diagnosis and management of nonmuscle invasive bladder cancer continue to evolve. Several of the principles of diagnosis and therapy have remained constant over the past few decades. However, overall survival outcome from bladder cancer does not appear to have changed significantly over the past few decades. Furthermore, despite significant scientific advancements and new discoveries, the basic approach to diagnosis of bladder cancer with cytology and endoscopy remain constant. So do the principles of intravesical therapy. Since the approval of BCG for intravesical use in 1987 and that of valrubicin, no other intravesical agents have been approved and adopted into widespread use. This provides us with both challenges and opportunities. In this issue of the Indian Journal of Urology, a series of articles focuses on diagnosis and management of NMIBC. The approach to risk stratification of NMIBC, while not new, is still not universally employed in guiding management. This could partly be due to the multitude of stratification schema that are available. A better understanding of the nuances of stratification and the differences and advantages of these schemas could be helpful in guiding the clinician in using them in an optimal manner. Two articles summarize the new advances in the endoscopic diagnosis of bladder cancer as well as the use of new urinary markers other than cytology. A contemporary review of intravesical chemotherapy and immunotherapy provide the salient attributes of each of these approaches and can serve to guide practitioners in maximizing the utility of such therapy. There are many investigators who have been developing salvage intravesical therapies as alternatives to standard chemo and immunotherapy. The data from these early studies are intriguing and encouraging and are summarized in an excellent overview. Finally, evidence-based guidelines would provide a sound overall framework for developing management approaches to these patients. The final article summarizes the currently available guideline-based management of NMIBC. These articles have been written in a manner that provides a summative and practical overview for the clinician. We hope that the readers will benefit from reading them as much as the authors and I have enjoyed writing them.
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